Search the Newsreel

Warren Foust Named President and CEO of STAAR Surgical, Deborah Andrews Transitions to Executive Vice President and CFO Roles

STAAR Surgical Company has appointed Warren Foust as its new President, Chief Executive Officer, and a board member, effective August 4, 2026. Foust previously served as interim co-CEO, president, and chief operating officer. Deborah Andrews, who served as interim co-CEO alongside Foust, will transition …

STAAR Surgical Reports More Than 4M Lenses Sold as CEO Changes

STAAR Surgical announced the appointment of Warren Foust as President and Chief Executive Officer, effective August 4, 2026, following an extensive global search. Foust, who previously served as Interim Co-CEO and President & Chief Operating Officer, will focus on revenue growth, profit expansion, and …

STAAR Surgical names Warren Foust CEO, Andrews to EVP and CFO

STAAR Surgical Company has appointed Warren Foust as President and CEO, and a new member of its Board of Directors, effective immediately. Deborah Andrews, who served as Interim Co-CEO alongside Foust, will now serve as Executive Vice President while continuing her role as Chief …

STAAR Surgical to discuss vision correction business Aug. 12

STAAR Surgical (NASDAQ: STAA) announced it will release its second-quarter 2026 financial results and a shareholder letter on August 12, 2026, after market close. The company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial performance, operational …

STAAR Surgical Company Revenue Breakdown – NASDAQ:STAA

This article provides a breakdown of STAAR Surgical Company's (NASDAQ: STAA) revenue. Last year, the company generated $239.44 million USD, with its top-performing segment, Non-consignment, contributing $178.99 million USD. The "Other" segment accounted for $93.84 million USD last year.

How (STAA) Movements Inform Risk Allocation Models

This article analyzes Staar Surgical Company (NASDAQ: STAA) movements, highlighting weak near and mid-term sentiment, but a neutral long-term outlook. It presents AI-generated institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging. The analysis also provides multi-timeframe signal …

STAAR Surgical Co (STAA) Institutional Confidence

STAAR Surgical Co (STAA) has an institutional shareholding score of 10.00, placing it first among 199 companies in the Healthcare Equipment & Supplies industry. Institutional shareholding increased by 10.75% quarter-over-quarter, with Steven Cohen being the largest institutional shareholder despite a decrease in his holdings. …

ETFs Investing in PT Sumber Tani Agung Resources Tbk Stocks

UBS Initiates STAAR Surgical at Sell With $20 Price Target

UBS has initiated coverage on STAAR Surgical (STAA) with a "Sell" rating and a price target of $20. This rating suggests a negative outlook for the medical equipment company. The article also mentions recent news and analyst updates regarding STAAR Surgical's performance, particularly in …

STAAR Surgical Company Revenue Breakdown – BX:SR3

STAAR Surgical Company (SR3) reported total revenue of 189.82 million CHF last year. Its top-performing segment, Non-consignment, contributed 141.90 million CHF, while "Other" accounted for 74.39 million CHF. The company's financial data is available on TradingView, detailing segments and regional performance.

STAAR Surgical Co (STAA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of STAAR Surgical Co (STAA), listing its major shareholders and their proportional holdings. It also provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activities including changes in holdings by key investors.

STAAR Surgical Co (STAA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of STAAR Surgical Co (STAA) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page includes current stock data and general company information but …

Can STAAR Surgical (STAA) Justify Its Valuation As Sales Guidance Tops $90 Million?

STAAR Surgical (STAA) has guided Q2 2026 net sales to over $90 million, significantly up from $44.3 million a year prior, making revenue momentum a key discussion point for investors. Despite a recent stock drop, its fair value is pegged at $29.67, above its …

Did STAAR Surgical’s Surging Q2 2026 Revenue Guidance Just Shift STAAR Surgical’s (STAA) Investment Narrative?

STAAR Surgical announced significantly raised revenue guidance for Q2 2026, expecting net sales to exceed US$90 million compared to US$44.3 million in Q2 2025. This surge, potentially driven by the FDA's expanded age indication for EVO ICLs, suggests strong business momentum and could reshape …

STAAR Surgical (STAA) Stock Could Be 12% Undervalued On Q2 Sales Recovery

STAAR Surgical's stock, despite a recent rebound, presents a mixed valuation picture. While the Discounted Cash Flow (DCF) model suggests it's 11.9% undervalued, traditional market multiples like the P/S ratio indicate it might be overvalued compared to its industry and fair ratio. The article …

STAAR Surgical Down Over 9%, On Pace for Largest Percent Decrease Since February 2025 -- Data Talk

STAAR Surgical (STAA) stock is down over 9% and is headed for its largest single-day percentage decrease since February 2025. This significant drop follows a period of notable gains, including a recent 2.41% increase on Friday. The article highlights key financial metrics including its …

STAAR Surgical, Globus Medical, Integer Holdings, and Enovis Stocks Trade Down, What You Need To Know

Shares of STAAR Surgical, Globus Medical, Integer Holdings, and Enovis all traded down after Intuitive Surgical warned that changes to insurance plans could slow U.S. procedure growth, raising fears of a sector-wide slowdown in the medical devices and supplies industry. The news suggests that …

Medical Device Stocks Decline Amid Insurance Changes

The medical device sector, particularly companies like STAAR Surgical, is experiencing declines due to investor concerns over insurance changes potentially slowing U.S. procedure growth, highlighted by Intuitive Surgical's warning. STAAR Surgical's stock dropped 10.1%, and despite some positive analyst sentiment and strong Q1 earnings, …

Caution Lingers for STAAR Surgical Amid Middle East Geopolitical Tensions

STAAR Surgical (NASDAQ: STAA) stock experienced a decline despite reporting strong preliminary Q2 net sales exceeding $90 million, driven by a rebound in China and solid momentum in the Americas. However, the company faced headwinds in the EMEA region due to geopolitical tensions in …

STAAR Surgical Q2 net sales more than double on growth in China, Asia-Pacific, Americas

STAAR Surgical’s Q2 net sales more than doubled year-over-year to $90 million, slightly missing analyst expectations for $90.26 million. This growth was primarily driven by strong performance in China and the broader Asia-Pacific region, alongside double-digit gains in the Americas. However, sales in EMEA …

Staar Surgical Dips 8.4% After Hours on Early Q2 Results

Staar Surgical (Nasdaq: STAA) saw its shares fall 8.4% in after-hours trading following the release of its preliminary Q2 sales. While the company expects revenue to exceed $90 million, a 123% increase year-over-year, specific sales in the EMEA region experienced a low single-digit decline …

STAAR Surgical reports Q2 sales to exceed $90 million

STAAR Surgical Company projects its second-quarter net sales to surpass $90 million, a significant increase from $44.3 million in the prior year's same period. Despite geopolitical and macroeconomic challenges, particularly in EMEA, the company experienced strong growth in China, the broader Asia-Pacific region, and …

STAAR Surgical Company Provides Consolidated Revenue Guidance for the Second Quarter Ended July 3, 2026

STAAR Surgical Company has issued consolidated revenue guidance for the second quarter ended July 3, 2026, anticipating net sales to exceed $90 million. This projection represents a significant increase compared to net sales of $44.3 million reported in the second quarter of 2025. The …

Medical Devices & Supplies - Specialty Stocks Q1 Earnings: STAAR Surgical (NASDAQ:STAA) Firing on All Cylinders

How The STAAR Surgical (STAA) Story Is Shifting After Q1 And New Analyst Targets

5 Must-Read Analyst Questions From STAAR Surgical’s Q1 Earnings Call

STAAR Surgical signals standalone strength as Alcon overhang fades after strong Q1

STAA Stock On Track For Its Fourth Straight Session Of Gains – This Analyst Would Rather Be Early Than Late On Staar’s Growth Story

Compared to Estimates, Staar Surgical (STAA) Q1 Earnings: A Look at Key Metrics

Staar Surgical (STAA) Tops Q1 Earnings and Revenue Estimates

STAAR Surgical (NASDAQ:STAA) Beats Expectations in Strong Q1 CY2026, Stock Jumps 18.3%

Earnings To Watch: STAAR Surgical (STAA) Reports Q1 Results Tomorrow

Staar Surgical (STAA) Earnings Expected to Grow: What to Know Ahead of Q1 Release

STAAR Surgical (STAA) Is Up 8.0% After Q1 2026 Sales More Than Double - What's Changed

STAAR Surgical: Q1 Preliminary Revenues Justify Decision To Reject Alcon Bid (NASDAQ:STAA)

China drives STAAR Surgical sales above $90M in early 2026